Germany· DE-A57-c98fecb3b5bae2d3
Hydroxycarbamid Hikma
A hydroxycarbamide product containing hydroxycarbamide, registered in Germany by Hikma Farmacêutica (Portugal), S.A.. The same ATC class is registered in 16 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Hydroxycarbamide is registered in 16 of 19 countries.
Countries holding a registration under ATC L01XX05 (hydroxycarbamide), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 10 of them publish a price we can compare per daily dose
Hydroxycarbamide · ATC L01XX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of hydroxycarbamide costs, country by country.
Normalised to the WHO defined daily dose (1.4 g), the median price runs from $0.51 in United States to $16.83 in France — a ×33 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Hydroxycarbamide · price per daily dose (1.4 g)
USD · FX 28 Sept 2026
- FR France$16.83
- CH Switzerland$2.74
- IT Italy$1.13
- US United States$0.51 (acquisition cost)
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Hydroxycarbamide
- Manufacturer
- Hikma Farmacêutica (Portugal), S.A.
- Country
- Germany (DE)
- ATC code
- L01XX05
- ATC class
- Hydroxycarbamide
- Defined daily dose
- 1.4 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
333 interactions on record for hydroxycarbamide.
Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Hydroxycarbamide · interactions on record
333 records
- 31 severe
- 101 moderate
- 15 minor
- 186 info
Most severe, free to view
- DidanosineJ05AF02severe
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Hydroxycarbamide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesDROXIAWaylis Therapeutics LLC
- United KingdomDroxia 300mg capsulesImported (United States)
- FinlandHydreaOrifarm Oy
- NetherlandsHydroxycarbamide Devatis 500mg, harde capsulesDevatis GmbH
- CzechiaHYDROXYCARBAMIDE PHARMACENTER
- NorwayHydreaCheplapharm
- SwedenHydrea 500 mg Kapsel, hårdCheplapharm Arzneimittel GmbH
- PolandHydroxycarbamid EugiaEugia Pharma (Malta) Ltd.
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Ardjaq, Hydroxycarbamid Devatis
- Belgium · Hydrea
- Bulgaria · Хидреа
- Cyprus · Hydreasyn
- Czechia · Litalir
- Denmark · Hydroxyurea Medac, Oribamide
- Estonia · Hydrea
- Spain · Hidroxicarbamida Hikma, Hidroxicarbamida Medac
- Finland · Hydrea, Hydroxyurea Medac
- France · Hydrea, Hydroxycarbamide Arrow
- United Kingdom (Northern Ireland) · Hydrea, Hydroxycarbamide
- Greece · Hydreasyn
- Croatia · Litalir, Xybaid
- Hungary · Hydroxycarbamide Pharmacenter, Litalir
- Ireland · Hydrea
- Iceland · Hydroxyurea Medac, Siklos
- Italy · Idrossicarbamide Aurobindo, Onco Carbide
- Liechtenstein · Siklos
- Lithuania · Hydrea
- Luxembourg · Hydrea, Hydroxycarbamid Devatis
- Latvia · Hydrea
- Malta · Hydroxycarbamide Eugia
- Netherlands · Hydroxycarbamide Devatis, Hydroxycarbamide Eugia
- Norway · Hydroxyurea Medac, Oribamide
- Poland · Hydroxycarbamid Eugia, Hydroxycarbamid Teva
- Portugal · Hidroxicarbamida Generis, Hidroxicarbamida Hikma
- Romania · Hydrea
- Sweden · Hydrea, Hydroxyurea Medac
- Slovenia · Hidroksisečnina Aptapharma, Litalir
- Slovakia · Hydroxykarbamid Medac, Xybaid
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e89c9072-897d-4eff-b893-bc2491e7a838 GET /v1/drugs/e89c9072-897d-4eff-b893-bc2491e7a838?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Hydroxycarbamide",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about hydroxycarbamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.